MSA-2是一种口服非核苷酸 STING 激动剂主打

    MSA-2 是一种口服非核苷酸 STING 激动剂，以具有纳摩尔亲和力的非共价二聚体形式与 STING 结合。MSA-2 对人的 STING 亚型 WT 和 HAQ 的 EC₅₀ 分别为 8.3 和 24 μM。MSA-2 在同基因小鼠肿瘤模型中显示抗肿瘤活性，刺激肿瘤分泌干扰素-β，诱导肿瘤消退，具有持久的抗肿瘤免疫，并与抗 PD-1 协同作用。

    体外研究：

   MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals^[1].
MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor^[1].